![]() |
|
|
1 Division of Clinical Investigation, Sloan-Kettering Institute for Cancer Research and the Department of Anesthesiology, Memorial Hospital for Cancer and Allied Diseases, New York, New York
A double-blind crossover evaluation of the relative analgesic potency of phenazocine to morphine was carried out-in a series of sequential studies in cancer patients with chronic pain. In terms of peak action, phenazocine was found to be 4.3 times as potent as morphine. In terms of total effects, the relative potency estimate was 3.2. Few volunteered or readily apparent side-effects were observed and those after phenazocine were similar to those after morphine in equianalgesic doses.
In a parallel crossover controlled experiment, the relative potency of phenazocine compared to morphine in terms of respiratory effects has been determined in nine healthy subjects.
, the relative potency, was calculated to be 6.28. Based on these results phenazocine appears to produce as much or more respiratory depression as does a conmparable analgesic dose of morphine.